Epilepsy Therapeutics Market is expected to grow at a CAGR of 3.2% during the forecast period. Epilepsy Therapeutics Market is expected to reach US$ 18.24 Bn. by 2029. Epilepsy therapeutics are medicines that are the starting treatment choice for almost all patients with multiple seizures. Seizures that are caused explainable causes are held to be in a patient suffering from epilepsy. These seizures are said to be caused by some past injury to the brain or some traumatic incident.To know about the Research Methodology:-Request Free Sample Report Rising awareness and technological advancements regarding the treatment possibilities and a large number of patients suffering from the disease globally expected driving factors in the global epilepsy therapeutics market. Lack of affordability and penetration of epilepsy treatment methods in developing regions and routine of prescribing the first generation anti-epileptic drugs over the second generation anti-epileptic drugs are estimated restraints to the market development. Based on the product type, the Second Generation Epilepsy Therapeutics expected to dominate the xx% market share during the forecast period. Third generation epilepsy therapeutics have been introduced the thereby possessing enhanced pharmacokinetics and pharmacodynamics. Moreover, the third generation epilepsy therapeutics have several diverse molecular mechanisms of action, thereby offering a novel and, specifically the inpatient population undergoing refractory seizures in the market during the forecast period. The hospital pharmacy segment is to dominate the xx% market share during the forecast period. The hospital pharmacy segment is a surge in the incidence of epilepsy, improving epilepsy diagnosis rate, increasing genetic disorders, and surging number of neurologists and epileptologists determination the hospital pharmacy segment of the global epilepsy therapeutics market. North America is expected to account for the xx% of market share of the Global Epilepsy Therapeutics Market during the forecast period. Because of the rapid rise in the geriatric population, an increase in the pool of patients, and surge in research and development to provide more efficient and advanced products. Furthermore, developing numbers of companies and their increasing mergers and acquisitions, rising government approvals for the different products are driving the epilepsy therapeutics market during the forecast period. The objective of the report is to present a comprehensive analysis of Global Epilepsy Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Epilepsy Therapeutics Market dynamics, structure by analyzing the market segments and project the Global Epilepsy Therapeutics Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product Portfolio, Growth strategies, and Regional presence in the Global Epilepsy Therapeutics Market make the report investor’s guide. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.
Epilepsy Therapeutics Market Scope: Inquire before buying
Global Epilepsy Therapeutics Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 14.63 Bn. Forecast Period 2023 to 2029 CAGR: 3.2% Market Size in 2029: US $ 18.24 Bn. Segments Covered: by Product First Generation Epilepsy Therapeutics Second Generation Epilepsy Therapeutics Third Generation Epilepsy Therapeutics by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Epilepsy Therapeutics Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Epilepsy Therapeutics Market, Key Players are
1. Pfizer Inc 2. Novartis AG 3. Teva Pharmaceutical Industries Ltd. 4. Eisai Co.Ltd 5. UCB S.A. 6. Amneal Pharmaceuticals LLC 7. Upsher-Smith Laboratories LLC 8. GlaxoSmithKline plc. 9. Bausch Health Companies Inc. 10. Sunovion Pharmaceuticals Inc 11. Zogenix Inc. 12. Supernus Pharmaceuticals Inc 13. Abbott 14. Neurelis 15. Johnson & Johnson Services Inc. 16. Sumitomo Dainippon Pharma Co. Ltd 17. Bausch Health 18. Sanofi 19. Takeda Pharmaceutical Company Limited 20. Marinus Pharmaceuticals Inc. Frequently Asked Questions: 1. Which region has the largest share in Global Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Market? Ans: The Global Market is growing at a CAGR of 3.2% during forecasting period 2023-2029. 3. What is scope of the Global Market report? Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Market? Ans: The important key players in the Global Market are – Pfizer Inc, Novartis AG, Teva Pharmaceutical Industries Ltd., Eisai Co.Ltd, UCB S.A., Amneal Pharmaceuticals LLC, Upsher-Smith Laboratories LLC, GlaxoSmithKline plc., Bausch Health Companies Inc., Sunovion Pharmaceuticals Inc, Zogenix Inc., Supernus Pharmaceuticals Inc, Abbott, Neurelis, Johnson & Johnson Services Inc., Sumitomo Dainippon Pharma Co. Ltd, Bausch Health, Sanofi, Takeda Pharmaceutical Company Limited, and Marinus Pharmaceuticals Inc. 5. What is the study period of this Market? Ans: The Global Market is studied from 2022 to 2029.
Global Epilepsy Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Epilepsy Therapeutics Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Epilepsy Therapeutics Market Analysis and Forecast 6.1. Global Epilepsy Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Epilepsy Therapeutics Market Analysis and Forecast, by Product Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Epilepsy Therapeutics Market Value Share Analysis, by Product Type 7.4. Global Epilepsy Therapeutics Market Size (US$ Bn) Forecast, by Product Type 7.5. Global Epilepsy Therapeutics Market Analysis, by Product Type 7.6. Global Epilepsy Therapeutics Market Attractiveness Analysis, by Product Type 8. Global Epilepsy Therapeutics Market Analysis and Forecast, by Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel 8.4. Global Epilepsy Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel 8.5. Global Epilepsy Therapeutics Market Analysis, by Distribution Channel 8.6. Global Epilepsy Therapeutics Market Attractiveness Analysis, by Distribution Channel 9. Global Epilepsy Therapeutics Market Analysis, by Region 9.1. Global Epilepsy Therapeutics Market Value Share Analysis, by Region 9.2. Global Epilepsy Therapeutics Market Size (US$ Bn) Forecast, by Region 9.3. Global Epilepsy Therapeutics Market Attractiveness Analysis, by Region 10. North America Epilepsy Therapeutics Market Analysis 10.1. Key Findings 10.2. North America Epilepsy Therapeutics Market Overview 10.3. North America Epilepsy Therapeutics Market Value Share Analysis, by Product Type 10.4. North America Epilepsy Therapeutics Market Forecast, by Product Type 10.4.1. First Generation Epilepsy Therapeutics 10.4.2. Second Generation Epilepsy Therapeutics 10.4.3. Third Generation Epilepsy Therapeutics 10.5. North America Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel 10.6. North America Epilepsy Therapeutics Market Forecast, by Distribution Channel 10.6.1. Hospital Pharmacy 10.6.2. Retail Pharmacy 10.6.3. Online Pharmacy 10.7. North America Epilepsy Therapeutics Market Value Share Analysis, by Country 10.8. North America Epilepsy Therapeutics Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Epilepsy Therapeutics Market Analysis, by Country 10.10. U.S. Epilepsy Therapeutics Market Forecast, by Product Type 10.10.1. First Generation Epilepsy Therapeutics 10.10.2. Second Generation Epilepsy Therapeutics 10.10.3. Third Generation Epilepsy Therapeutics 10.11. U.S. Epilepsy Therapeutics Market Forecast, by Distribution Channel 10.11.1. Hospital Pharmacy 10.11.2. Retail Pharmacy 10.11.3. Online Pharmacy 10.12. Canada Epilepsy Therapeutics Market Forecast, by Product Type 10.12.1. First Generation Epilepsy Therapeutics 10.12.2. Second Generation Epilepsy Therapeutics 10.12.3. Third Generation Epilepsy Therapeutics 10.13. Canada Epilepsy Therapeutics Market Forecast, by Distribution Channel 10.13.1. Hospital Pharmacy 10.13.2. Retail Pharmacy 10.13.3. Online Pharmacy 10.14. North America Epilepsy Therapeutics Market Attractiveness Analysis 10.14.1. By Product Type 10.14.2. By Distribution Channel 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Epilepsy Therapeutics Market Analysis 11.1. Key Findings 11.2. Europe Epilepsy Therapeutics Market Overview 11.3. Europe Epilepsy Therapeutics Market Value Share Analysis, by Product Type 11.4. Europe Epilepsy Therapeutics Market Forecast, by Product Type 11.4.1. First Generation Epilepsy Therapeutics 11.4.2. Second Generation Epilepsy Therapeutics 11.4.3. Third Generation Epilepsy Therapeutics 11.5. Europe Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel 11.6. Europe Epilepsy Therapeutics Market Forecast, by Distribution Channel 11.6.1. Hospital Pharmacy 11.6.2. Retail Pharmacy 11.6.3. Online Pharmacy 11.7. Europe Epilepsy Therapeutics Market Value Share Analysis, by Country 11.8. Europe Epilepsy Therapeutics Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Epilepsy Therapeutics Market Analysis, by Country 11.10. Germany Epilepsy Therapeutics Market Forecast, by Product Type 11.10.1. First Generation Epilepsy Therapeutics 11.10.2. Second Generation Epilepsy Therapeutics 11.10.3. Third Generation Epilepsy Therapeutics 11.11. Germany Epilepsy Therapeutics Market Forecast, by Distribution Channel 11.11.1. Hospital Pharmacy 11.11.2. Retail Pharmacy 11.11.3. Online Pharmacy 11.12. U.K. Epilepsy Therapeutics Market Forecast, by Product Type 11.12.1. First Generation Epilepsy Therapeutics 11.12.2. Second Generation Epilepsy Therapeutics 11.12.3. Third Generation Epilepsy Therapeutics 11.13. U.K. Epilepsy Therapeutics Market Forecast, by Distribution Channel 11.13.1. Hospital Pharmacy 11.13.2. Retail Pharmacy 11.13.3. Online Pharmacy 11.14. France Epilepsy Therapeutics Market Forecast, by Product Type 11.14.1. First Generation Epilepsy Therapeutics 11.14.2. Second Generation Epilepsy Therapeutics 11.14.3. Third Generation Epilepsy Therapeutics 11.15. France Epilepsy Therapeutics Market Forecast, by Distribution Channel 11.15.1. Hospital Pharmacy 11.15.2. Retail Pharmacy 11.15.3. Online Pharmacy 11.16. Italy Epilepsy Therapeutics Market Forecast, by Product Type 11.16.1. First Generation Epilepsy Therapeutics 11.16.2. Second Generation Epilepsy Therapeutics 11.16.3. Third Generation Epilepsy Therapeutics 11.17. Italy Epilepsy Therapeutics Market Forecast, by Distribution Channel 11.17.1. Hospital Pharmacy 11.17.2. Retail Pharmacy 11.17.3. Online Pharmacy 11.18. Spain Epilepsy Therapeutics Market Forecast, by Product Type 11.18.1. First Generation Epilepsy Therapeutics 11.18.2. Second Generation Epilepsy Therapeutics 11.18.3. Third Generation Epilepsy Therapeutics 11.19. Spain Epilepsy Therapeutics Market Forecast, by Distribution Channel 11.19.1. Hospital Pharmacy 11.19.2. Retail Pharmacy 11.19.3. Online Pharmacy 11.20. Rest of Europe Epilepsy Therapeutics Market Forecast, by Product Type 11.20.1. First Generation Epilepsy Therapeutics 11.20.2. Second Generation Epilepsy Therapeutics 11.20.3. Third Generation Epilepsy Therapeutics 11.21. Rest of Europe Epilepsy Therapeutics Market Forecast, by Distribution Channel 11.21.1. Hospital Pharmacy 11.21.2. Retail Pharmacy 11.21.3. Online Pharmacy 11.22. Europe Epilepsy Therapeutics Market Attractiveness Analysis 11.22.1. By Product Type 11.22.2. By Distribution Channel 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Epilepsy Therapeutics Market Analysis 12.1. Key Findings 12.2. Asia Pacific Epilepsy Therapeutics Market Overview 12.3. Asia Pacific Epilepsy Therapeutics Market Value Share Analysis, by Product Type 12.4. Asia Pacific Epilepsy Therapeutics Market Forecast, by Product Type 12.4.1. First Generation Epilepsy Therapeutics 12.4.2. Second Generation Epilepsy Therapeutics 12.4.3. Third Generation Epilepsy Therapeutics 12.5. Asia Pacific Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel 12.6. Asia Pacific Epilepsy Therapeutics Market Forecast, by Distribution Channel 12.6.1. Hospital Pharmacy 12.6.2. Retail Pharmacy 12.6.3. Online Pharmacy 12.7. Asia Pacific Epilepsy Therapeutics Market Value Share Analysis, by Country 12.8. Asia Pacific Epilepsy Therapeutics Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Epilepsy Therapeutics Market Analysis, by Country 12.10. China Epilepsy Therapeutics Market Forecast, by Product Type 12.10.1. First Generation Epilepsy Therapeutics 12.10.2. Second Generation Epilepsy Therapeutics 12.10.3. Third Generation Epilepsy Therapeutics 12.11. China Epilepsy Therapeutics Market Forecast, by Distribution Channel 12.11.1. Hospital Pharmacy 12.11.2. Retail Pharmacy 12.11.3. Online Pharmacy 12.12. India Epilepsy Therapeutics Market Forecast, by Product Type 12.12.1. First Generation Epilepsy Therapeutics 12.12.2. Second Generation Epilepsy Therapeutics 12.12.3. Third Generation Epilepsy Therapeutics 12.13. India Epilepsy Therapeutics Market Forecast, by Distribution Channel 12.13.1. Hospital Pharmacy 12.13.2. Retail Pharmacy 12.13.3. Online Pharmacy 12.14. Japan Epilepsy Therapeutics Market Forecast, by Product Type 12.14.1. First Generation Epilepsy Therapeutics 12.14.2. Second Generation Epilepsy Therapeutics 12.14.3. Third Generation Epilepsy Therapeutics 12.15. Japan Epilepsy Therapeutics Market Forecast, by Distribution Channel 12.15.1. Hospital Pharmacy 12.15.2. Retail Pharmacy 12.15.3. Online Pharmacy 12.16. ASEAN Epilepsy Therapeutics Market Forecast, by Product Type 12.16.1. First Generation Epilepsy Therapeutics 12.16.2. Second Generation Epilepsy Therapeutics 12.16.3. Third Generation Epilepsy Therapeutics 12.17. ASEAN Epilepsy Therapeutics Market Forecast, by Distribution Channel 12.17.1. Hospital Pharmacy 12.17.2. Retail Pharmacy 12.17.3. Online Pharmacy 12.18. Rest of Asia Pacific Epilepsy Therapeutics Market Forecast, by Product Type 12.18.1. First Generation Epilepsy Therapeutics 12.18.2. Second Generation Epilepsy Therapeutics 12.18.3. Third Generation Epilepsy Therapeutics 12.19. Rest of Asia Pacific Epilepsy Therapeutics Market Forecast, by Distribution Channel 12.19.1. Hospital Pharmacy 12.19.2. Retail Pharmacy 12.19.3. Online Pharmacy 12.20. Asia Pacific Epilepsy Therapeutics Market Attractiveness Analysis 12.20.1. By Product Type 12.20.2. By Distribution Channel 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Epilepsy Therapeutics Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Epilepsy Therapeutics Market Overview 13.3. Middle East & Africa Epilepsy Therapeutics Market Value Share Analysis, by Product Type 13.4. Middle East & Africa Epilepsy Therapeutics Market Forecast, by Product Type 13.4.1. First Generation Epilepsy Therapeutics 13.4.2. Second Generation Epilepsy Therapeutics 13.4.3. Third Generation Epilepsy Therapeutics 13.5. Middle East & Africa Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel 13.6. Middle East & Africa Epilepsy Therapeutics Market Forecast, by Distribution Channel 13.6.1. Hospital Pharmacy 13.6.2. Retail Pharmacy 13.6.3. Online Pharmacy 13.7. Middle East & Africa Epilepsy Therapeutics Market Value Share Analysis, by Country 13.8. Middle East & Africa Epilepsy Therapeutics Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Epilepsy Therapeutics Market Analysis, by Country 13.10. GCC Epilepsy Therapeutics Market Forecast, by Product Type 13.10.1. First Generation Epilepsy Therapeutics 13.10.2. Second Generation Epilepsy Therapeutics 13.10.3. Third Generation Epilepsy Therapeutics 13.11. GCC Epilepsy Therapeutics Market Forecast, by Distribution Channel 13.11.1. Hospital Pharmacy 13.11.2. Retail Pharmacy 13.11.3. Online Pharmacy 13.12. South Africa Epilepsy Therapeutics Market Forecast, by Product Type 13.12.1. First Generation Epilepsy Therapeutics 13.12.2. Second Generation Epilepsy Therapeutics 13.12.3. Third Generation Epilepsy Therapeutics 13.13. South Africa Epilepsy Therapeutics Market Forecast, by Distribution Channel 13.13.1. Hospital Pharmacy 13.13.2. Retail Pharmacy 13.13.3. Online Pharmacy 13.14. Rest of Middle East & Africa Epilepsy Therapeutics Market Forecast, by Product Type 13.14.1. First Generation Epilepsy Therapeutics 13.14.2. Second Generation Epilepsy Therapeutics 13.14.3. Third Generation Epilepsy Therapeutics 13.15. Rest of Middle East & Africa Epilepsy Therapeutics Market Forecast, by Distribution Channel 13.15.1. Hospital Pharmacy 13.15.2. Retail Pharmacy 13.15.3. Online Pharmacy 13.16. Middle East & Africa Epilepsy Therapeutics Market Attractiveness Analysis 13.16.1. By Product Type 13.16.2. By Distribution Channel 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Epilepsy Therapeutics Market Analysis 14.1. Key Findings 14.2. South America Epilepsy Therapeutics Market Overview 14.3. South America Epilepsy Therapeutics Market Value Share Analysis, By Product Type 14.4. South America Epilepsy Therapeutics Market Forecast, by Product Type 14.4.1. First Generation Epilepsy Therapeutics 14.4.2. Second Generation Epilepsy Therapeutics 14.4.3. Third Generation Epilepsy Therapeutics 14.5. South America Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel 14.6. South America Epilepsy Therapeutics Market Forecast, by Distribution Channel 14.6.1. Hospital Pharmacy 14.6.2. Retail Pharmacy 14.6.3. Online Pharmacy 14.7. South America Epilepsy Therapeutics Market Value Share Analysis, by Country 14.8. South America Epilepsy Therapeutics Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Epilepsy Therapeutics Market Forecast, by Product Type 14.9.1. First Generation Epilepsy Therapeutics 14.9.2. Second Generation Epilepsy Therapeutics 14.9.3. Third Generation Epilepsy Therapeutics 14.10. Brazil Epilepsy Therapeutics Market Forecast, by Distribution Channel 14.10.1. Hospital Pharmacy 14.10.2. Retail Pharmacy 14.10.3. Online Pharmacy 14.11. Mexico Epilepsy Therapeutics Market Forecast, by Product Type 14.11.1. First Generation Epilepsy Therapeutics 14.11.2. Second Generation Epilepsy Therapeutics 14.11.3. Third Generation Epilepsy Therapeutics 14.12. Mexico Epilepsy Therapeutics Market Forecast, by Distribution Channel 14.12.1. Hospital Pharmacy 14.12.2. Retail Pharmacy 14.12.3. Online Pharmacy 14.13. Rest of South America Epilepsy Therapeutics Market Forecast, by Product Type 14.13.1. First Generation Epilepsy Therapeutics 14.13.2. Second Generation Epilepsy Therapeutics 14.13.3. Third Generation Epilepsy Therapeutics 14.14. Rest of South America Epilepsy Therapeutics Market Forecast, by Distribution Channel 14.14.1. Hospital Pharmacy 14.14.2. Retail Pharmacy 14.14.3. Online Pharmacy 14.15. South America Epilepsy Therapeutics Market Attractiveness Analysis 14.15.1. By Product Type 14.15.2. By Distribution Channel 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Pfizer Inc 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Manufacturing Footprint 15.3.2. Novartis AG 15.3.3. Teva Pharmaceutical Industries Ltd. 15.3.4. Eisai Co.Ltd 15.3.5. UCB S.A. 15.3.6. Amneal Pharmaceuticals LLC 15.3.7. Upsher-Smith Laboratories LLC 15.3.8. GlaxoSmithKline plc. 15.3.9. Bausch Health Companies Inc. 15.3.10. Sunovion Pharmaceuticals Inc 15.3.11. Zogenix Inc. 15.3.12. Supernus Pharmaceuticals Inc 15.3.13. Abbott 15.3.14. Neurelis 15.3.15. Johnson & Johnson Services Inc. 15.3.16. Sumitomo Dainippon Pharma Co. Ltd 15.3.17. Bausch Health 15.3.18. Sanofi 15.3.19. Takeda Pharmaceutical Company Limited 15.3.20. Marinus Pharmaceuticals Inc. 16. Primary Key Insights